Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer

Radiotherapy and Oncology

Volumn 114, Issue 3, 2015, Pages 302-309

  Valentini, Vincenzo ^a   Van Stiphout, Ruud G P M ^b,c   Lammering, Guido ^b   Gambacorta, Maria A ^a   Barba, Maria C ^a   Bebenek, Marek ^d   Bonnetain, Franck ^e   Bosset, Jean F ^f   Bujko, Krzysztof ^g   Cionini, Luca ^h   Gerard, Jean P ⁱ   Rödel, Claus ^j   Sainato, Aldo ^h   Sauer, Rolf ^k   Minsky, Bruce D ^l   Collette, Laurence ^m   Lambin, Philippe ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d Silesian Oncological Centre   (Poland)

^e Faculté Médecine Dijon   (France)

^f UNIVERSITY HOSPITAL OF BESANÇON   (France)

^g INSTITUTE OF ONCOLOGY   (Poland)

^h UNIVERSITY HOSPITAL OF PISA   (Italy)

ⁱ CENTRE ANTOINE LACASSAGNE   (France)

^j GOETHE UNIVERSITY   (Germany)

^k UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^m EORTC DATA CENTER   (Belgium)

more..

Author keywords

Disease free survival; Pathological complete response; Personalized treatment; Prediction models; Rectal cancer; Risk ratio

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RECTUM CANCER; TREATMENT RESPONSE; BIOASSAY; BIOLOGICAL MODEL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTAL NEOPLASMS; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECTAL NEOPLASMS; YOUNG ADULT;

EID: 84927574514     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2015.02.001     Document Type: Article

References (18)

1. R. Sullivan, J. Peppercorn, K. Sikora, J. Zalcberg, N.J. Meropol, and E. Amir Delivering affordable cancer care in high-income countries Lancet Oncol 12 2011 933 980
2. D. Sargent, Q. Shi, G. Yothers, E. Van Cutsem, J. Cassidy, and L. Saltz Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803 Eur J Cancer 47 2011 990 996
3. M. Lambrecht, C. Deroose, S. Roels, V. Vandecaveye, F. Penninckx, and X. Sagaert The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer Acta Oncol 49 2010 956 963
4. Y. Wang, B. Cummings, P. Catton, L. Dawson, J. Kim, and J. Ringash Primary radical external beam radiotherapy of rectal adenocarcinoma: long term outcome of 271 patients Radiother Oncol 77 2005 126 132
5. C. Capirci, V. Valentini, L. Cionini, A. De Paoli, C. Rodel, and R. Glynne-Jones Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients Int J Radiat Oncol Biol Phys 72 2008 99 107
6. M. Maas, P.J. Nelemans, V. Valentini, P. Das, C. Rodel, and L.J. Kuo Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data Lancet Oncol 11 2010 835 844
7. R. Gelman, R. Gelber, I.C. Henderson, C.N. Coleman, and J.R. Harris Improved methodology for analyzing local and distant recurrence J Clin Oncol 8 1990 548 555
8. J.F. Bosset, L. Collette, G. Calais, L. Mineur, P. Maingon, and L. Radosevic-Jelic Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 355 2006 1114 1123
9. J.P. Gerard, T. Conroy, F. Bonnetain, O. Bouche, O. Chapet, and M.T. Closon-Dejardin Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203 J Clin Oncol 24 2006 4620 4625
10. R. Sauer, H. Becker, W. Hohenberger, C. Rodel, C. Wittekind, and R. Fietkau Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 2004 1731 1740
11. K. Bujko, M.P. Nowacki, A. Nasierowska-Guttmejer, W. Michalski, M. Bebenek, and M. Kryj Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer Br J Surg 93 2006 1215 1223
12. A. Sainato, V. Cernusco Luna Nunzia, V. Valentini, A. De Paoli, and E.R. Maurizi No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT) Radiother Oncol 113 2014 Nov 223 229
13. V. Valentini, R.G. van Stiphout, G. Lammering, M.A. Gambacorta, M.C. Barba, and M. Bebenek Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials J Clin Oncol 29 2011 3163 3172
14. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
15. J.D. Kalbfleisch, and R.L. Prentice The statistical analysis of failure time data 2nd ed. 2002 John Wiley & Sons Hoboken (NJ) USA
16. J.R. Anderson, K.C. Cain, and R.D. Gelber Analysis of survival by tumor response J Clin Oncol 1 1983 710 719
17. F. Bonnetain, J.F. Bosset, J.P. Gerard, G. Calais, T. Conroy, and L. Mineur What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question? Eur J Cancer 48 2012 1781 1790
18. A. Habr-Gama, R.O. Perez, I. Proscurshim, F.G. Campos, W. Nadalin, and D. Kiss Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy J Gastrointest Surg 10 10 2006 1319 1328 [discussion 28-9]